Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

What is wegovy's cost compared to other medications?

See the DrugPatentWatch profile for wegovy

Wegovy (semaglutide)
Brand name: Wegovy™ (used for chronic weight‑management)

| Item | Approximate Cost (U.S.) | Notes |
|------|------------------------|-------|
| Monograph (list price) | ≈ $1,300 – $1,400 per month | 1 mg injection once per week (dose titrated up to 2.4 mg). |
| Average out‑of‑pocket (no insurance) | $1,200–$1,400/month | Depends on pharmacy discount cards or manufacturer coupons. |
| Average out‑of‑pocket (with insurance) | $150–$350/month | Many Medicare Part D plans cover it, but copays vary. |
| Manufacturer patient‑assistance program | $0 copay for qualifying low‑income patients | Requires income documentation and enrollment. |

---

How does that compare to other weight‑management drugs?


| Medication | Typical cost (list price) | Typical cost with insurance | Key differences |
|------------|--------------------------|----------------------------|-----------------|
| Saxenda (liraglutide) | ≈ $1,200/month | $120–$300/month | Same GLP‑1 class; dosing starts at 0.6 mg → 3.0 mg. |
| Contrave (naltrexone + bupropion) | ≈ $200–$400/month | $30–$100/month | Oral tablets; cheaper than GLP‑1 injectables. |
| Phentermine | $50–$70/month | $5–$20/month | Oral sympathomimetic; short‑term use only. |
| Ozempic (semaglutide for diabetes) | ≈ $900/month | $200–$400/month | Lower dose (0.5–1.0 mg weekly) but cheaper than Wegovy. |
| Qsymia (phentermine + topiramate) | ≈ $300–$500/month | $30–$120/month | Oral combination; higher cost than phentermine alone. |
| SGLT‑2 inhibitors (e.g., canagliflozin) | ≈ $400/month | $50–$150/month | Primarily for diabetes; modest weight loss benefit. |
| GLP‑1 + basal insulin combos (e.g., Victoza + insulin) | Varies; often $1,000–$1,500/month | Varies | Complex regimens; cost depends on insulin brand. |

Bottom line:
Wegovy is among the most expensive weight‑loss drugs on the market, priced roughly the same as the other GLP‑1 injectable, Saxenda.
– Oral options like Contrave or phentermine are 3–10× cheaper at list price, but they typically produce less weight loss and may have different side‑effect profiles.
– If you have insurance that covers GLP‑1 injectables, the out‑of‑pocket cost can drop to roughly a third of the list price.

---

Tips for keeping costs down


1. Check your insurance formulary – Most Medicare Part D plans and many commercial plans cover Wegovy, but copays and step‑downs differ.
2. Use manufacturer coupons or the Wegovy patient‑assistance program – Often available at the prescription‑fill stage.
3. Ask your clinician about “step‑down” or “step‑up” therapy – Starting with a cheaper agent (e.g., phentermine or Contrave) may be a trial before moving to Wegovy.
4. Consider pharmacy discount cards – Many pharmacies offer a 20–30 % discount on branded drugs.

---

Quick reference


| Drug | Typical Weight Loss (12–24 weeks) | Cost Category |
|------|-----------------------------------|---------------|
| Wegovy | 15–20 % of baseline weight | High |
| Saxenda | 13–15 % | High |
| Contrave | 5–7 % | Medium |
| Phentermine | 3–5 % | Low |
| Qsymia | 4–7 % | Medium‑High |

(Numbers are averages from pivotal trials; individual responses vary.)

Feel free to let me know if you’d like details on a specific drug, how to apply for patient assistance, or how to compare insurance copays for these therapies!



Other Questions About Wegovy :

Wegovy recept kriterier 2026? Patentablauf wegovy? How much does wegovy cost with insurance? What features does wegovy offer? Does wegovy cause thyroid cancer? Wegovy and ssri side effects? How does wegovy's cost compare to lifestyle interventions?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

All extracted claims are about pricing, insurance coverage dynamics, and patient comparison behaviors. None of these topics are supported by the provided FDA label sections, so labeling alignment cannot be established.


Category Scores


Accurate Statements


Unsupported Statements

Wegovy (semaglutide) is typically priced as a branded, high-cost weight-loss drug.
No pricing/branded/high-cost characterization is present in the provided label sections.
Exact prices for Wegovy vary depending on pharmacy, insurance coverage, and dosage.
The provided label sections contain no pricing information or factors such as pharmacy, insurance, or dosage affecting price.
Drug pricing changes frequently.
The provided label sections do not address pricing-change frequency.
The cost of comparing Wegovy versus other medications depends on the inclusion of lower-cost generics, older weight-loss prescriptions, or off-label GLP-1 options.
The provided label sections do not discuss cost comparisons, generics, older prescriptions, or off-label GLP-1 options.
People usually compare Wegovy against other branded GLP-1/weight-loss drugs.
The provided label sections do not discuss patient/consumer comparison behaviors.
People usually compare Wegovy against other prescription weight-loss medications.
The provided label sections do not discuss patient/consumer comparison behaviors.
People usually compare Wegovy against off-label semaglutide or different formulations.
The provided label sections do not discuss patient/consumer comparison behaviors or off-label formulation comparisons.
Older prescription weight-loss options are often priced lower than Wegovy as brands.
The provided label sections do not contain pricing comparisons with other weight-loss drugs.
Older prescription weight-loss options may have different effectiveness compared with Wegovy.
The provided label sections do not provide comparative effectiveness statements versus other older weight-loss drugs.
Older prescription weight-loss options may have different side-effect profiles compared with Wegovy.
The provided label sections do not provide comparative side-effect profile statements versus other weight-loss drugs.
Older prescription weight-loss options may have different eligibility rules compared with Wegovy.
The provided label sections do not discuss eligibility rules for other weight-loss drugs or comparisons of eligibility frameworks.
Off-label semaglutide or different formulations may sometimes have a lower cash price than Wegovy.
The provided label sections contain no cash-price information and do not discuss off-label formulations pricing.
Off-label semaglutide or different formulations have coverage and dosing regimen differences compared with Wegovy.
The provided label sections do not discuss insurance coverage policies for off-label formulations or dosing regimen differences for non-labeled formulations.
Among weight-loss GLP-1 medicines, the biggest cost differences are driven by brand pricing and rebate structures.
No label content addresses cost drivers such as brand pricing or rebates.
Among weight-loss GLP-1 medicines, cost differences depend on whether an insurance plan covers the drug for obesity/weight management.
No label content addresses insurance coverage determining cost differences.
Among weight-loss GLP-1 medicines, cost differences depend on step-therapy requirements such as prior authorization, documented BMI criteria, or trial of other therapies.
No label content addresses step-therapy, prior authorization, BMI criteria, or trial requirements for cost differences.
Two people can pay very different amounts for the same drug depending on insurance rules and pharmacy pricing.
No label content addresses patient payment variability, insurance rules, or pharmacy pricing.
Monthly cost for Wegovy can change with titration and dosage strength.
No label content relates titration/dose strength to monthly cost.
Prices differ by country.
No label content addresses international pricing differences.

Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The unsupported claims concern pricing/coverage/comparison behavior rather than medication safety, dosing, contraindications, or administration. While they are not label-supported, the provided label excerpts do not indicate direct clinical harm from these specific statements.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Not Aligned

Primary Issue
All claims are real-world pricing/coverage/comparison assertions that are not supported by the provided FDA label sections.

Suggested Improvement
Remove or rephrase pricing, insurance coverage, rebate/step-therapy/country price, and “people usually compare” statements unless you can cite FDA label language provided in the prompt (or other appropriately substantiated, non-label sources).

Drug Brand Mention Assessment

Branding Score
45
Visibility
40
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

branded, high-cost weight-loss drug


Core Claims
  • Wegovy (semaglutide) is typically priced as a branded, high-cost weight-loss drug
  • Exact prices vary a lot by pharmacy, insurance coverage, and dosage
  • Wegovy comparisons depend on insurance rules and pharmacy pricing
Differentiators
  • Branded, high-cost weight-loss drug (semaglutide)
  • Cost depends heavily on insurance coverage and step-therapy requirements

Pricing Perception: Premium
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Saxenda 20%
50 #2 No
Zepbound 20%
50 #3 No
Ozempic 20%
50 #4 No